Conjugation of blocked ricin to an Anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization

Blood

Volumn 90, Issue 6, 1997, Pages 2364-2375

  Goulet, Anne Christine ^b   Goldmacher, Victor S ^b   Lambert, John M ^b   Baron, Chantal ^b   Roy, Denis Claude ^b   Kouassi, Edouard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; IMMUNOTOXIN; LACTOSE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 19; RICIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONJUGATION; DIMERIZATION; DOSE TIME EFFECT RELATION; DRUG POTENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION;

EID: 0030881185     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2364.2364_2364_2375     Document Type: Article

References (54)

1. Tedder TF, Isaacs CM: Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol 143:712, 1989
2. Stamenkovic I, Seed B: CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 168:1205, 1988
3. Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman SF: B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244, 1983
4. Fearon DT, Carter RH: The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity. Annu Rev Immunol 13:127, 1995
5. Matsumoto AK, Martin DR, Carter RH, Klickstein LB, Ahearn JM, Fearon DT: Functional dissection of the CD21/CD19/TAPA-1/ Leu-13 complex of B lymphocytes. J Exp Med 178:1407, 1993
6. Bradbury L, Kansas GS, Levy S, Evans RL, Tedder TF: CD19 is a component of a signal transduction complex on the surface of B cells that includes CD21, TAPA-1 and Leu 13. J Immunol 149:2841, 1992
7. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF: Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD 19 signal transduction molecule. Immunity 3:39, 1995
8. Rickert RC, Rajewsky K, Roes J: Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376:352, 1995
9. Sato S, Steeber DA, Tedder TF: The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA 92:11558, 1995
10. Tedder TF, Zhou LJ, Engel: The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 15:437, 1994
11. Chalupny NJ, Aruffo A, Esselstyn JM, Chan PY, Bajorath J, Blake J, Gilliland LK, Ledbetter JA, Tepper MA: Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains. Eur J Immunol 25:2978, 1995
12. Roifman CM, Ke S: CD19 is a substrate of the antigen receptor-associated protein tyrosine kinase in human B cells. Biochem Biophys Res Commun 194:222, 1993
13. Uckun FM, Burkhardt AL, Jarvis L, Jun X, Stealey B, Dibirdik I, Myers DE, Tuel-Ahlgren L, Bolen JB: Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J Biol Chem 268:21172, 1993
14. Carter RH, Tuveson DA, Park DJ, Rhee SG, Fearon DT: The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 147:3663, 1991
15. Bradbury LE, Goldmacher VS, Tedder TF: The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. J Immunol 151:2915, 1993
16. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA: Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD 19 immunotoxins. Blood 71:13, 1988
17. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424, 1984
18. Pulczynski S, Boesen AM, Jensen OM: Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: An immunofluorescence and immunoelectron microscopy study. Blood 81:1549, 1993
19. Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blättler WA, Collison AR, Stewart JK, Chong LD, Cook S, Slayter HS, Beaumont E, Watkins S: Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J Cell Physiol 141:222, 1989
20. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906, 1989
21. Ghetie M, May R, Till M, Uhr J: Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignat human B-cells as potential reagents for in vivo therapy. Cancer Res 48:2610, 1988
22. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA: An immunotoxin prepared with blocked ricin: A natural plant toxin adapted for therapeutic use. Cancer Res 51:6236, 1991
23. Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, Goldmacher VS, Blättler WA: The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 30:3234, 1991
24. Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM: Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin. Cancer Res 52:4200, 1992
25. Goldmacher VS, Lambert JM, Blättler WA: The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: Evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 183:758, 1992
26. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81:2263, 1993
27. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL, Nadler LM: Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11:726, 1993
28. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA, Taylor JA, Nadler LM: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 79:576, 1992
29. Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J: Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol 15:51, 1995
30. Roy DC, Gyger M, Bélanger R, Perreault C, Bonny Y, Soiffer R, Esseltine D, Ritz J: Engraftment following autologous bone marrow transplantation with anti-B4-bR depleted marrow for patients with B-cell malignancies. Blood 82:81a, 1993 (abstr)
31. Minta A, Kao JPY, Tsien RY: Fluorescent indicators for cytosolic calcium based on rhodamin and fluorescein. J Biol Chem 264:8171, 1989
32. Kelley KA: Sample station modification providing on-line reagent addition and reduced transit time for flow cytometers. Cytometry 10:796, 1989
33. Venkatesh YP, Bottomley S, Lambert JM: Self-association of blocked ricin: Consequence of covalently blocking the galactose-binding sites of ricin by glycopeptide affinity ligands, in Van Driessche E, Fischer J, Beeckmans S, Beg-Hansen TC (eds): Lectins: Biology, Biochemistry, Clinical Biochemistry (vol 10). Hellerup, Denmark, Textop, 1994, p 194
34. Weng WK, Jarvis L, LeBien TW: Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J Biol Chem 269:32514, 1994
35. Venkatesh YP, Lambert JM: Galactose-induced dimerization of blocked ricin at acidic pH: Evidence for a third galactose-binding site in ricin B-chain. Glycobiol (in press)
36. Fu T, Burbage C, Tagge E, Chandler J, Willingham M, Frankel A: Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding. Evidence for more than two lectin sites on the ricin toxin B chain. Bioconjugate Chem 7:651, 1996
37. Goldmacher VS, Anderson J, Schulz ML, Blättler WA, Lambert JM: Somatic cell mutants resistant to ricin, diphteria toxin, and immunotoxins. J Biol Chem 262:3205, 1987
38. Lankester AC, Van Schijndel GMW, Rood PML, Verhoeven AJ, Van Lier RAW: B cell antigen receptor cross-linking induces tyrosine phosphorylation and membrane translocation of a multimeric Shc complex that is augmentaed by CD19 co-ligation. Eur J Immunol 24:2818, 1994
39. Carter RH, Fearon DT: CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105, 1992
40. Rijkers GT, Griffioen AW, Zegers BJM, Cambier JC: Ligation of membrane immunoglobulin leads to inactivation of the signal-transduction ability of membrane immunoglobulin, CD19, CD21, and B-call gp95. Proc Natl Acad Sci USA 87:8766, 1990
41. Pesando JM, Bouchard LS, McMaster BE: CD 19 is functionally and physically associated with surface immunoglobulin. J Exp Med 170:2159, 1989
42. Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F: Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol 23:2407, 1993
43. Maloney MD, Lingwood CA: CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med 180:191, 1994
44. Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walserh TF, Lee HC: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 262:1056, 1993
45. +-dependent internalization of the transmembrane glycoprotein CD38 in human Namalwa B cells. FEBS Lett 396:327, 1996
46. De Rie MA, Schumacher TNM, Van Schijndel GMW, Van Lier RAW, Miedema F: Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell Immunol 118:368, 1989
47. Rigley KP, Callard RE: Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: Anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4. Eur J Immunol 21:535, 1991
48. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992
49. i regulation in apoptosis, oncosis, and necrosis. Biochim Biophys Acta 1313:173, 1996
50. Clapham DE: Calcium signaling. Cell 80:259, 1995
51. Ghosh A, Greenberg ME: Calcium signaling in neurons: Molecular mechanisms and cellular consequences. Science 268:239, 1995
52. Harman AW, Maxwell MJ: An evaluation of the role of calcium in cell injury. Ann Rev Pharmacol Toxicol 35:129, 1995
53. Sandvig K, Olnes S: Entry of the toxic proteins abrin, modeccin, ricin, and diphteria toxin into cells. I. Requirement for calcium. J Biol Chem 257:7495, 1982
54. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC: Anti-CD38-blocked ricin: An immunotoxin for the treatment of multiple myeloma. Blood 84:3017, 1994